Description

Methyl Ergonovine Maleate Tablets (0.125 mg / 0.2 mg)

Healthy Inc is a premier global supplier of high-stability obstetric and gynecological therapies. We provide premium Methyl Ergonovine Maleate Tablets (also known as Methylergometrine), manufactured in WHO–GMP certified specialized hormonal and ergoline units. As a lifesaving uterotonic agent, this product is a vital export for maternity hospitals, labor & delivery wards, and Ministry of Health (MOH) tenders in Southeast Asia, Africa, and Latin America.

Product Overview

Methyl Ergonovine is a semi-synthetic analogue of the natural ergot alkaloid, ergometrine. It is specifically engineered to provide a rapid and sustained tetanic contraction of the uterine smooth muscle, making it a definitive treatment for uterine atony and postpartum bleeding.

The “Postpartum Safety” Specialist:

• Mechanism of Action: Methyl Ergonovine acts directly on the smooth muscle of the uterus, increasing the tone, rate, and amplitude of rhythmic contractions. It primarily stimulates alpha-adrenergic and serotonergic receptors, leading to a forceful contraction that compresses bleeding vessels at the placental site.
• Rapid Uterotonic Effect: Following oral administration, the onset of action is relatively fast (5–10 minutes), providing a sustained effect that lasts for several hours, which is critical for preventing the recurrence of uterine atony.
• Selective Potency: Unlike other ergot alkaloids, Methyl Ergonovine is more selective for the uterus and has a lower tendency to induce significant peripheral vasoconstriction or hypertension at therapeutic doses.

Technical & Manufacturing Specifications

Formulated for absolute dosage precision and protection against light-induced degradation.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from ISO 9001:2015 certified units.

• Photosensitivity Protocol: Methyl Ergonovine is highly sensitive to light. Our manufacturing is conducted under actinic-safe lighting, and tablets are finished with an opaque coating to ensure molecular integrity until the point of use.
• Micro-Dose Precision: Due to the extremely low drug load (0.2 mg), we utilize trituration and validated geometric mixing to ensure 100% content uniformity, preventing sub-therapeutic dosing in emergency settings.
• Stability Validation: Validated for Zone IVb (40°C / 75% RH). Our specialized coating prevents the oxidation of the ergoline ring, ensuring a reliable 24-month shelf life in tropical export markets.

Therapeutic Indications & Clinical Symptoms

• Postpartum Hemorrhage (PPH): Management and prevention of hemorrhage following the delivery of the placenta.
• Uterine Atony: Treatment of failure of the uterus to contract after childbirth or abortion.
• Post-Abortion Bleeding: Routine management to ensure uterine involution and minimize blood loss.
• Subinvolution: Treatment of the uterus when it fails to return to its normal size after childbirth.

Dosage & Administration

• Standard Adult Dose: 0.2 mg (one tablet) 3 to 4 times daily in the puerperium for a maximum of one week.
• Contraindications: Must not be used in cases of hypertension, pre-eclampsia, or pregnancy (before the delivery of the infant) due to the risk of uterine rupture or fetal distress.
• Safety Note: Breastfeeding is generally discouraged during treatment as the drug may be excreted in milk and can inhibit lactation (prolactin inhibition).

Global Export & Contract Manufacturing Services

Healthy Inc is a verified Pharmaceutical Exporter in Mumbai, catering to Maternity Hospital Chains and Ministry of Health Tenders. We offer Third Party Manufacturing for Methyl Ergonovine with full CTD Dossier and COPP support. Our logistics network facilitates secure transit to Vietnam, Nigeria, Kenya, and Brazil, providing WHO-GMP quality at competitive B2B prices.

Commercial Inquiries

WhatsApp/Call: +91 7710003340
Email: info@healthyinc.co.in